Abstract:Autophagy inhibition could hinder the underlying protective mechanisms in the course of tumor treatment. The advances in autophagy inhibition have driven focus on the functionalized nanoplatforms by combining the current treatment paradigms with complementary autophagy inhibition for enhanced efficacy. Furthermore, Ca2+ overload is also a promising adjuvant target for the tumor treatment by augmenting mitochondrial damage. In this view, complementary mitochondrial Ca2+ overload and autophagy inhibition were first demonstrated as a novel strategy suitable for homing in on the shortage of photodynamic therapy (PDT). We constructed biodegradable tumor-targeted inorganic/organic hybrid nanocomposites (DPGC/OI) synchronously encapsulating IR780 and Obatoclax by biomineralization of the nanofilm method, which consists of pH-triggered calcium phosphate (CP), long circulation phospholipid block copolymers 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-poly(ethylene glycol) (PEG)2000-glucose (DPG). In the presence of the hydrophilic PEG chain and glucose transporter 1 (Glut-1) ligands, DPGC would become an effectively tumor-oriented nanoplatform. Subsequently, IR780 as an outstanding photosensitizer could produce increased amounts of toxic reactive oxygen species (ROS) after laser irradiation. Calcium phosphate (CP) as the Ca2+ nanogenerator could generate Ca2+ at low pH to induce mitochondrial Ca2+ overload. The dysfunction of mitochondria could enhance increased amounts of ROS. Based on the premise that autophagy would degrade dysfunctional organelles to sustain metabolism and homeostasis, which might participate in resistance to PDT, Obatoclax as an autophagy inhibitor would hinder the protective mechanism from cancer cells with negligible toxicity. Such an enhanced PDT via mitochondrial Ca2+ overload and autophagy inhibition could be realized by DPGC/OI.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c11583.Scanning electron microscope (SEM) imaging of CP, DPGC, and DPGC/OI (Figure S1); size distribution of DPGC/OI in serum (Figure S2); FT-IR of CP, DPGC, and DSPE-PEG-glucose (Figure S3); TEM images of DPGC/OI after incubation for 0.5 h in (Figure S4A) pH 5.2 and (Figure S4B) pH 7.4, respectively; temperature curves of IR780 + NIR and DPGC/OI + NIR after 1 min laser irradiation (Figure S5); release profiles of IR780 and Obatoclax from DPGC/OI (Figure S6A,B); CLSM images of 4T1 cancer cells treated with DPGC/I at different time points (Figure S7); ROS generation in 4T1 cells after treatment with IR780 and CP/I upon laser exposure after 48 h (Figure S8); matching histogram analysis of cleaved Caspase-3 (Figure S9); live and dead images of 4T1 cells treated with different treatments for 48 h (Figure S10); histogram Individual blood analysis of mice at 15 days after different treatments (Figure S11); tumors dissected from mice after 15 days with H&E and TUNEL staining (Figure S12); H&E staining of tissues collected from mice after 15 days of different treatments, scale bar = 200 μm (Figure S13); relative volume changes (Figure S14A) and mice body weight changes in different groups (Figure S14B), data are mean ± SD, n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 vs control; photographs of tumors ex vivo in different treatment groups within 15 days (Figure S14C) (PDF)This article has not yet been cited by other publications.

Inhibition of Pro‐Survival Autophagy Induced by Rare‐Earth Nanocomposites for Promoting Photothermal Therapy of Visualized Tumors

Biomimetic Metallacage Nanoparticles with Aggregation-Induced Emission for NIR-II Fluorescence Imaging-Guided Synergistic Immuno-Phototherapy of Tumors

In situ autophagy regulation in synergy with phototherapy for breast cancer treatment

Harnessing copper-palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer

An intelligent ZIF-8-gated polydopamine nanoplatform for in vivo cooperatively enhanced combination phototherapy

An Ultrasmall PVP-Fe-Cu-Ni-S Nano-agent for Synergistic Cancer Therapy through triggering Ferroptosis and Autophagy

Blocking Autophagic Flux Enhances Iron Oxide Nanoparticle Photothermal Therapeutic Efficiency in Cancer Treatment.

Colloidally Stabilized DSPE-PEG-Glucose/Calcium Phosphate Hybrid Nanocomposites for Enhanced Photodynamic Cancer Therapy via Complementary Mitochondrial Ca 2+ Overload and Autophagy Inhibition

Autophagy Blockage Enhancing Photothermal and Chemodynamic Synergistic Therapy Based on HCQ/CuS Nanoplatform

Heparin-Coated Photosensitive Metal–Organic Frameworks as Drug Delivery Nanoplatforms of Autophagy Inhibitors for Sensitized Photodynamic Therapy against Breast Cancer

Engineering mitochondrial uncoupler synergistic photodynamic nanoplatform to harness immunostimulatory pro-death autophagy/mitophagy

Propranolol-induced autophagic dysfunction combined with a targeted metal-organic framework as a novel strategy for improving antitumor therapeutic efficacy

Fluorescent hyaluronic acid nanoprodrug: A tumor-activated autophagy inhibitor for synergistic cancer therapy

Potentiating dual-directional immunometabolic regulation with nanomedicine to enhance anti-tumor immunotherapy following incomplete photothermal ablation

Targeted regulation of autophagy using sorafenib-loaded biomineralization nanoenzyme for enhanced photodynamic therapy of hepatoma

A minimalist dendrimer nanodrug for autophagy inhibition-amplified tumor photothermo-immunotherapy

Drug repurposing-based nanoplatform via modulating autophagy to enhance chemo-phototherapy against colorectal cancer

Bismuth Embedded Silica Nanoparticles Loaded with Autophagy Suppressant to Promote Photothermal Therapy.

A Photothermal-Hypoxia Sequentially Activatable Phase-Change Nanoagent for Mitochondria-Targeting Tumor Synergistic Therapy

Two-dimensional persistent luminescence “optical battery” for autophagy inhibition-augmented photodynamic tumor nanotherapy

Environment-responsive dopamine nanoplatform for tumor synergistic therapy